Efficacy of a Probiotic and Herbal Supplement in Models of Lung Inflammation

Wenger, Nancy; Qiao, Luhua; Nicola, Teodora; Nizami, Zoha; Xu, Xin; Willis, Kent A.; Ambalavanan, Namasivayam; Gaggar, Amit; Lal, Charitharth Vivek

doi:10.3390/microorganisms10112136

Cited by 4 publications

(4 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Herbal extracts of holy basil leaf, turmeric root, and vasaka leaf can be taken orally to support antioxidant, antitussive, anti-inflammatory, and bronchodilatory effects in the lungs and systemically (17-19). A blend of live Lactobacillus strains with holy basil, turmeric, and vasaka extracts, decreased matrix metalloproteinase 9 (MMP-9) pathway activity, neutrophil recruitment, and pro-inflammatory biomarkers in preclinical in vitro and in vivo models of lung inflammation (20).…”

Section: Introductionmentioning

confidence: 99%

“…Our group has focused on attenuating inflammation and supporting lung function through the gut-lung axis using oral probiotic supplementation. In this clinical study, we hypothesized that a preclinically studied (20) Lactobacillus probiotic and herbal blend would demonstrate safety and preliminary biomarker and clinical improvements in healthy and asthmatic populations in a 1-month course of dosing.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Clinical Trial of a Probiotic and Herbal Supplement for Lung and Gut Health

Wenger

Qiao

Nicola

et al. 2023

Preprint

Self Cite

View full text Add to dashboard Cite

Rationale: Dysbiosis of the gut microbiome may augment lung disease via the gut-lung axis. Proteobacteria may increase MMP-9 release and contribute to tissue proteolysis followed by neutrophil recruitment, lung tissue injury, and perpetuation of chronic lung disease. Trial Design: We sought to determine if a probiotic and herbal blend was safe and well-tolerated in healthy volunteers and asthmatic patients. Methods: We conducted a 1-month randomized, open-label clinical trial in Cork, Ireland with healthy and asthmatic patients who took the blend twice a day. The primary endpoint was safety with secondary endpoints including quality of life, lung function, gut microbiome ecology, and inflammatory biomarkers. Results: All subjects tolerated the blend without adverse events. Asthmatic subjects who took the blend showed significant improvements in lung function and serum short chain fatty acid levels from baseline to Week 4. The gut microbiome of asthmatic subjects differed significantly from controls, with the most prominent difference in the relative abundance of the proteobacteria Escherichia coli. Administration of the probiotic maintained overall microbial community architecture with the only significant difference being an increase in absolute abundance of the probiotic strains measured by strain-specific PCR. Conclusions: This study supports the safety and efficacy potential of oral probiotic administration of the probiotic and herbal to act on the gut-lung axis.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Clinical Trial of a Probiotic and Herbal Supplement for Lung and Gut Health

Wenger

Qiao

Nicola

et al. 2023

Preprint

Self Cite

View full text Add to dashboard Cite

show abstract

“…Herbal extracts of holy basil leaf, turmeric root, and vasaka leaf can be taken orally to support antioxidant, antitussive, anti-inflammatory, and bronchodilatory effects in the lungs and systemically ( 21–23 ). A blend of live Lactobacillus strains with holy basil, turmeric, and vasaka extracts, decreased matrix metalloproteinase 9 (MMP-9) pathway activity, neutrophil recruitment, and pro-inflammatory biomarkers in preclinical in vitro and in vivo models of lung inflammation ( 24 ).…”

Section: Introductionmentioning

confidence: 99%

“…Our group has focused on attenuating inflammation and supporting lung function through the gut-lung axis using oral probiotic supplementation. In this clinical study, we hypothesized that a preclinically studied ( 24 ) Lactobacillus probiotic and herbal blend would demonstrate safety and preliminary biomarker and clinical improvements in healthy and asthmatic populations in a 1-month course of dosing.…”

Section: Introductionmentioning

confidence: 99%

Clinical trial of a probiotic and herbal supplement for lung health

et al. 2023

Self Cite

View full text Add to dashboard Cite

IntroductionDysbiosis of the gut microbiome may augment lung disease via the gut-lung axis. Proteobacteria may contribute to tissue proteolysis followed by neutrophil recruitment, lung tissue injury, and perpetuation of chronic inflammation. To study the effects of probiotics across the gut-lung axis, we sought to determine if a Lactobacillus probiotic and herbal blend was safe and well-tolerated in healthy volunteers and asthmatic patients.MethodsWe conducted a 1-month randomized, open-label clinical trial in Cork, Ireland with healthy and asthmatic patients who took the blend twice a day. The primary endpoint was safety with exploratory endpoints including quality of life, lung function, gut microbiome ecology, and inflammatory biomarkers.ResultsAll subjects tolerated the blend without adverse events. Asthmatic subjects who took the blend showed significant improvements in lung function as measured by forced expiratory volume and serum short chain fatty acid levels from baseline to Week 4. The gut microbiome of asthmatic subjects differed significantly from controls, with the most prominent difference in the relative abundance of the proteobacteria Escherichia coli. Administration of the probiotic maintained overall microbial community architecture with the only significant difference being an increase in absolute abundance of the probiotic strains measured by strain-specific PCR.ConclusionThis study supports the safety and efficacy potential of a Lactobacillus probiotic plus herbal blend to act on the gut-lung axis. However, due to the lack of a control group, a longer blinded, placebo-controlled study will be warranted to confirm the efficacy improvements observed in this trial.Clinical trial registrationhttps://clinicaltrials.gov/, identifier NCT05173168.

show abstract